Meta-analysis: 25%-31% of silent corticotroph adenomas recur after primary treatment

  • J Clin Endocrinol Metab

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A systematic review and meta-analysis suggest that silent corticotroph adenomas (SCAs) have a 25%-31% recurrence rate after primary treatment, similar to other nonfunctioning pituitary adenoma (NFPA) subtypes.

Why this matters

  • Studies comparing the recurrence rates of SCAs with other NFPA subtypes have shown conflicting results.

Key results

  • The recurrence rate was 5.96 (95% CI, 4.30-7.84) per 100 person-years.
    • 5.41 (95% CI, 3.28-7.96) per 100 person-years after surgery alone and
    • 4.88 (95% CI, 0.67-11.54) per 100 person-years after surgery plus radiotherapy.
  • In studies with mean follow-up
  • In studies with mean follow-up ≥5 years, the recurrence rate was 31%.
  • SCAs and other NFPA subtypes had similar recurrence rates (recurrence rate ratio [RRR], 1.44; P=.13).
    • RRR, 1.17 (P=.43) in patients treated with surgery alone.

Study design

  • 14 studies with 297 patients were included in the meta-analysis.
  • Funding: None.

Limitations

  • Moderate risk for bias in included studies.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit